Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences. Events include a poster on AGMB-447 for idiopathic pulmonary fibrosis at the ATS International Conference and multiple fireside chats and investor meetings across New York, London, San Diego, and Boston.
On the day this news was published, AGMB declined 1.25%, reflecting a mild negative market reaction.
This price movement removed approximately $8M from the company's valuation, bringing the market cap to $600.33M at that time.
This announcement details a busy calendar of scientific and investor engagements, including an AGMB-...
Analysis
This announcement details a busy calendar of scientific and investor engagements, including an AGMB-447 poster at the ATS International Conference 2026 and multiple fireside chats and one-on-one meetings through July 15, 2026. In the past year Agomab has raised capital via IPO and reported cash expected to fund operations into the first half of 2029, alongside progress for ontunisertib and AGMB-447. Investors may watch upcoming trial initiations, data readouts, and partnering signals alongside feedback from these conferences.
Key Figures
Poster board number:904ATS poster time:8:15 AM ETATS poster date:May 20, 2026+5 more
8 metrics
Poster board number904ATS International Conference 2026 poster on AGMB-447
ATS poster time8:15 AM ETAGMB-447 poster presentation on May 20, 2026
ATS poster dateMay 20, 2026AGMB-447 poster at ATS International Conference 2026
Closing of IPO of 12,500,000 ADSs at $16.00, raising $200M gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has shown mixed reactions: positive fundamental updates sometimes aligned with gains, while clearly positive IP and pipeline news once coincided with a notable selloff.
Recent Company History
Over the last few months, Agomab moved from its February 2026 IPO to reporting full-year 2025 results and confirming its 2026 outlook, with cash of €116.5M and IPO proceeds expected to fund operations into the first half of 2029. It also secured a U.S. patent for AGMB-447 covering composition of matter through at least 2041. Against that backdrop, this announcement simply outlines a busy slate of scientific and investor conferences, extending ongoing investor and scientific outreach rather than changing fundamentals.
Regulatory & Risk Context
Short Interest: 1.7%
Short Interest
1.7% of shares outstanding
as of 2026-05-29Days to cover: 18.43
Key Terms
TGFβR1/ALK5 inhibitor, idiopathic pulmonary fibrosis, preclinical species
3 terms
TGFβR1/ALK5 inhibitormedical
"AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment..."
A TGFβR1/ALK5 inhibitor is a drug that blocks the TGF‑β receptor type 1 (also called ALK5), shutting down a cell‑signaling pathway that can drive scarring, abnormal tissue growth, or cancer progression. Think of it as turning down a faulty alarm bell that tells cells to change behavior. Investors care because these molecules are the basis for new therapies with large potential markets but also carry clinical and regulatory risk tied to trial results, safety and clear patient selection.
idiopathic pulmonary fibrosismedical
"Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic..."
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
preclinical speciesmedical
"Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and..."
Preclinical species are the animals used in laboratory studies to test a new drug or medical product before it is tried in humans. Like crash‑testing cars with dummies, these studies reveal safety, dosing and basic effects so regulators and developers can judge whether a candidate is worth advancing; positive or negative results in those species strongly affect program risk, timelines and investor expectations.
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:
ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
BIO International Convention. Monday, June 22 - Thursday, June 25, 2026 in San Diego, CA.
2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.
About Agomab Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.
Contacts Investors Sofie Van Gijsel VP of Investor Relations E-Mail: sofie.vangijsel@agomab.com Phone: +1 781 296 1143
When will Agomab Therapeutics (NASDAQ: AGMB) present AGMB-447 data at ATS International Conference 2026?
Agomab will present a poster on AGMB-447 at ATS International Conference 2026 on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, Florida, highlighting preclinical and healthy subject data in idiopathic pulmonary fibrosis.
What is Agomab Therapeutics' AGMB-447 and what data will be shared in May 2026?
AGMB-447 is described as an inhaled lung-restricted TGFβR1/ALK5 inhibitor intended for idiopathic pulmonary fibrosis. According to Agomab, the ATS 2026 poster will report robust anti-fibrotic activity and target engagement in preclinical species and healthy subjects.
Which investor conferences will Agomab Therapeutics (AGMB) attend in May 2026?
Agomab plans to join the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ for a fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET, and the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026 at 8:00 AM ET in New York.
What are the June 2026 conference plans for Agomab Therapeutics (NASDAQ: AGMB)?
In June 2026, Agomab is scheduled to participate in the JPM European Healthcare Symposium on Wednesday, June 10, 2026 in London, UK, and the BIO International Convention from June 22–25, 2026 in San Diego, California.
Will Agomab Therapeutics (AGMB) hold one-on-one investor meetings in 2026?
Yes. According to Agomab, the company plans one-on-one investor meetings at the 2026 Leerink Partners Therapeutics Forum on Wednesday, July 15, 2026 in Boston, Massachusetts, giving investors direct access to management for questions on its fibro-inflammation pipeline.
